Where, following a notification as referred to in Article 46, the Commission or a Member State considers, on the basis of casualties or hospitalisations of persons in the Union due to exposure to falsified medicinal products, that rapid action is required to protect public health, the Commission shall assess the notification without delay and at the latest within 45 days.
Art. 47 Regulation (EU) 2016/161
Evaluation of the notifications
Opinion of Advocate General Szpunar delivered on 13 January 2022. Novartis Pharma GmbH v Abacus Medicine A/S.Decision
… bij de herverpakking van geneesmiddelen, gelijkwaardig is aan het oorspronkelijke middel tegen knoeien, in de zin van artikel 47 bis, lid 1, onder b), van deze richtlijn, zelfs wanneer bij een controle op grond van artikel 16, 20 of 25 van …
13 Jan 2022 · 62020CC0147
Regulation (EU) 2021/1686Lawamends
Článek 47 nařízení Komise v přenesené pravomoci (EU) 2016/161 [Nařízení Komise v přenesené pravomoci (EU) 2016/161 ze dne 2. října 2015, kterým se doplňuje směrnice Evropského parlamentu a Rady 2001/83/ES stanovením …
Changed on 11 Oct 2021
Where, following a notification as referred to in Article 46, the Commission or a Member State considers, on the basis of casualties or hospitalisations of citizens ofpersons in the Union due to exposure to falsified medicinal products, that rapid action is required to protect public health, the Commission shall assesassess the notification without delay and at the latest within 45 days.
- 11 Oct 2021 – todayin force
- 2 Oct 2015 – 11 Oct 2021earlier wording